Back to results
US 6,503,752 B1Granted
Lymphotropic agents and vectors
AssigneeRamot University Authority for Applied Research and Industrial Development Ltd.
InventorNitza Frenkel
Life of this patent
Estimating the term…
Abstract
Human herpes virus (HHV) 7 is capable of binding to the CD4 antigen and the HHV-7 or a binding protein derived therefrom is thus useful as a CD4-ligand for various therapeutic applications. HHV-6 or HHV-7 are lymphotropic and are thus useful as lymphotropic vectors for delivering DNA into lymphocytes.
Claims7
A recombinant DNA molecule comprising:
- (a) a DNA sequence encoding HHV-6 or HHV-7, said DNA sequence encoding HHV-6 or HHV-7 comprising an origin of replication, a promoter sequence which induces expression in a T-cell host and a cleavage and packaging signal;
- and
- (b) a foreign nucleic acid sequence selected from the group consisting of a sequence coding for Thymidine Kinase, a sequence coding for glucocerebrosidase, a sequence coding for an insulin growth factor, a sequence coding for an insulin-like growth factor, a sequence coding for a protein which inhibits proliferation of malignant cells, a sequence coding for a protein which protects non-malignant cells from toxic effects of radiation, a sequence coding for a protein which protects non-malignant cell from toxic effects of chemotherapeutic agents, and combinations thereof.
A recombinant DNA molecule comprising:
- (a) a DNA sequence encoding HHV-6 or HHV-7, said DNA sequence encoding HHV-6 or HHV-7 comprising an origin of replication, a promoter sequence which induces expression in a T-cell host and a cleavage and packaging signal;
- and
- (b) a foreign nucleic acid sequence, wherein said foreign nucleic acid sequence encodes a sequence which is an antisense sequence to an oncogene active in malignant lymphatic cells.
Dependencies are inferred from the claim text.